
Inventiva is a clinical-stage biopharmaceutical company focused on developing oral small molecule therapies for patients with significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. Its lead candidate, lanifibranor, is a pan-PPAR agonist in Phase 3 trials for NASH/MASH with breakthrough therapy designation from the FDA. The company has built an extensive proprietary molecule library and wholly-owned R&D capabilities inherited from Abbott, Solvay, and Fournier.
Create a free account to see funding visualizations and detailed round data.
Create Free AccountCreate a free account to see full funding history, valuations, and investor participation.
Create Free AccountCreate a free account to see which investors have funded this company.
Create Free Account